Literature DB >> 23566655

Adrenal myelolipoma: a mingle of progenitor cells?

Chenchen Feng1, Haowen Jiang, Qiang Ding, Hui Wen.   

Abstract

Adrenal myelolipoma (AML) is a rare benign tumour composed or mature haematopoietic tissue and fat. The tumour is functionally inert and is usually detected incidentally. Mainly introduced in case reports, the tumourigenesis of AML is poorly understood with 3 historical hypotheses seemingly unrelated to each other. Here we propose the tumourigenic pathway based on the novel findings on stem/progenitor cell and our preliminary data. We hypothesize the tumourigenesis as follows: the fat components are derived by the mesenchymal stem cells of stromal fat of adrenal cortex under certain stimuli. Mature adipocytes begin to accumulate and become inflammatory stimulating neighbouring adrenal cortex tissue to release possibly G-CSF to recruit circulating haematopoietic progenitors. During the tumour growth, haematopoietic cell in the central part acquire energy from burning the surrounding fat until they are fully differentiated and division stops. Lacking the ability to further grow, the central part undergoes necrosis and calcification whilst the peripheral part continues to slowly pile up newly derived adipocytes and haematopoietic progenitor cells. The necrosis or calcification of the tumour the inflammation persists and the tumour generates a self-growing signalling loop, entailing a continuous growth even without further stimuli. Our theory offers a logical explanation to the diverse phenomena identified on AML and unifies the historical theories. Future studies may focus on the stem/progenitor cell profiles of AML to confirm and supplement our hypothesis.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566655     DOI: 10.1016/j.mehy.2013.03.021

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  Adrenal myelolipoma: a comprehensive review.

Authors:  Ábel Decmann; Pál Perge; Miklós Tóth; Peter Igaz
Journal:  Endocrine       Date:  2017-11-21       Impact factor: 3.633

Review 2.  Adrenal myelolipomas.

Authors:  Jan Calissendorff; Carl Christofer Juhlin; Anders Sundin; Irina Bancos; Henrik Falhammar
Journal:  Lancet Diabetes Endocrinol       Date:  2021-08-24       Impact factor: 32.069

Review 3.  Adrenal myelolipoma: Controversies in its management.

Authors:  Vasanth G Shenoy; Anuroop Thota; Ravi Shankar; Mallikarjun G Desai
Journal:  Indian J Urol       Date:  2015 Apr-Jun

4.  Giant bilateral adrenal myelolipoma with congenital adrenal hyperplasia.

Authors:  S Al-Bahri; A Tariq; B Lowentritt; D V Nasrallah
Journal:  Case Rep Surg       Date:  2014-07-16

5.  Coexistence of Myelolipoma and Primary Bilateral Macronodular Adrenal Hyperplasia With GIP-Dependent Cushing's Syndrome.

Authors:  Stéphanie Larose; Louis Bondaz; Livia M Mermejo; Mathieu Latour; Odile Prosmanne; Isabelle Bourdeau; André Lacroix
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-11       Impact factor: 5.555

6.  A rare case of adrenal collision tumor: Myelolipoma and schwannoma in the adrenal gland.

Authors:  Mariangela Gomez; Rohin Mehta
Journal:  SAGE Open Med Case Rep       Date:  2020-05-09

7.  Adrenal myelolipoma: To operate or not? A case report and review of the literature.

Authors:  Mary Ramirez; Subhasis Misra
Journal:  Int J Surg Case Rep       Date:  2014-06-18

8.  Adrenal myelolipoma: from tumorigenesis to management.

Authors:  Wassim Alaoui Mhammedi; Hicham Ouslim; Abdelghani Ouraghi; Mohammed Irzi; Amine Elhoumaidi; Amine Elhoumaidi; Mehdi Chennoufi; Mohammed Mokhtari; Anouar Elmouden; Ali Barki
Journal:  Pan Afr Med J       Date:  2019-12-05

9.  Primary hepatic myelolipoma: A case report and review of the literature.

Authors:  Ke-Yu Li; Ai-Lin Wei; Ang Li
Journal:  World J Clin Cases       Date:  2020-10-06       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.